JAGSNPHARM2024-04-012024-06-30 JAGSNPHARM2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member JAGSNPHARM2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member JAGSNPHARM2024-06-30 JAGSNPHARM2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 507789 JAGSNPHARM NOTLISTED Jagsonpal Pharmaceuticals Limited Equity 2024-04-01 2025-03-31 2024-08-07 2024-07-31 INR Millions First quarter 17:40:00 18:25:00 2024-08-07 2024-08-07 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Standalone 614390000.00 14440000.00 628830000.00 43870000.00 200340000.00 -21170000.00 147390000.00 2150000.00 10720000.00 141580000.00 524880000.00 103950000.00 -32850000.00 71100000.00 15870000.00 1940000.00 17810000.00 0.00 53290000.00 0.00 0.00 0.00 0.00 53290000.00 -480000.00 52810000.00 0.00 0.00 132290000.00 5 1.94 1.93 0.00 0.00 1.94 1.93 1. The unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2. The Company is primarily engaged in manufacturing and trading of pharmaceutical products (including active pharmaceutical ingredients) to its customers in India and overseas, which is being considered as a single reportable business segment by the chief operating decision maker. Other Expenses 117330000.00 Share Based Payment Expenses 24250000.00 Item that will not be reclassified to profit and loss -640000.00 -640000.00 -160000.00 0.00